(Reuters) -U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center in Indiana that will focus on developing new ways to manufacture its drugs and increasing production of experimental medicines used in clinical studies.
Lilly and Danish rival Novo Nordisk are market leaders for a class of weight-loss treatments known as GLP-1 agonists, which work by suppressing appetite. Some analysts expect this market will reach $150 billion by the early 2030s.
While its widely popular drugs Zepbound and Mounjaro have launched in the U.S., Lilly has several other obesity and neurological disease drugs in development…